Sitryx Regains Rights to SYX-1042 Itaconate Mimetic from Lilly Following Portfolio Reprioritization

Sitryx Therapeutics has regained the rights to SYX-1042, an itaconate mimetic for chronic autoimmune and inflammatory diseases, from Lilly following portfolio reprioritization. The candidate progressed successfully through Lilly's Phase 1 clinical trial and is now part of Sitryx's portfolio of novel small molecule candidates targeting major autoimmune indications. Sitryx will assess how to prioritize SYX-1042 for further development or partnering.

Sitryx Therapeutics has regained the rights to SYX-1042, an itaconate mimetic for chronic autoimmune and inflammatory diseases, from Eli Lilly & Company (Lilly) following a strategic portfolio reprioritization. The oral candidate, which has first-in-class potential, successfully completed Lilly's Phase 1 clinical trial in healthy volunteers. With the return of SYX-1042 to Sitryx, the company now assesses how to prioritize the candidate for further in-house development or potential partnering.

SYX-1042 is part of Sitryx's portfolio of novel small molecule candidates targeting major autoimmune indications with high unmet need. The candidate's progression through a successful Phase 1 clinical trial has provided Sitryx with robust preclinical and clinical data to evaluate its potential. Sitryx's Chief Executive Officer, Iain Kilty, commented on the collaboration with Lilly, stating, "Through our partner Lilly’s investment in the clinical development of SYX-1042, this program has progressed significantly, delivering positive first-in-human data. We will be reviewing this clinical data alongside the robust preclinical data package to determine the optimal path forward."

Sitryx, established in 2018, has raised $85 million to date from an international syndicate of specialist investors, including SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Eli Lilly and Company, and GSK. The company is headquartered in Oxford, UK, and focuses on developing novel oral therapies to restore immune balance in autoimmune and inflammatory diseases.

References:
[1] https://www.globenewswire.com/news-release/2025/08/08/3130265/0/en/Sitryx-regains-rights-to-SYX-1042-itaconate-mimetic-for-chronic-autoimmune-and-inflammatory-diseases-from-Lilly-following-portfolio-reprioritization.html